< Back to latest news & events

Knowledge Hub

Paul Sanderson

September 2021

We are sorry to announce that Paul Sanderson is leaving HGF on 30 September 2021.

Paul joined HGF in February 2002 to establish HGF Law, becoming CEO of the wider HGF Group in June 2004, stepping down 17 years later in June 2021.

During his tenure as CEO, Paul transformed HGF from a small, 3-office business into one of the leading IP firms in Europe with 22 offices in 7 jurisdictions, 55 partners and more than 450 staff. Turnover increased 11-fold from £8.3 million to c.£90 million, with profits rising 20-fold from £0.9 million to £18 million.

Paul has made an exceptional contribution to HGF, which would not be the firm it is without him. On behalf of all Paul’s partners and colleagues we thank him for his vision, drive and leadership and wish him all the very best for the future.

Latest updates

The FoodTech Series #1 | Multi-parameter claims, examples outside the scope of the claims: when improvement occurs and evidence becomes easier to demonstrate

            The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they ruled on an opposition …

Read article

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article